CONCORD BIOTECH
|
The Current P/E Ratio of CONCORD BIOTECH is 51.49.
| Share Price | ₹1,330.0 | Oct 08,2026 |
| Market Cap | ₹13,911.3 Cr | |
| Earnings-TTM | ₹270.2 Cr | TTM-Consolidated Results |
| Price/Earnings | 51.49x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of CONCORD BIOTECH
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹13,911.3 Cr] as on Oct 08,2026
(/) Earnings [ ₹270.2 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 51.49x ]
Thus, for CONCORD BIOTECH , the investors are currently willing to pay 51.49 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of CONCORD BIOTECH !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of CONCORD BIOTECH over the last five years.
Historical PE (Price/Earnings) ratio chart of CONCORD BIOTECH
PE Ratio Performance Analysis for CONCORD BIOTECH
- CONCORD BIOTECH 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 27.92x.
- CONCORD BIOTECH 's operated at median p/e ratio of 40.73x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, CONCORD BIOTECH 's p/e ratio peaked in Mar2024 at 51.68x.
- CONCORD BIOTECH 's p/e ratio hit its five-year low in Mar2023 of 0x.
How does CONCORD BIOTECH 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| CONCORD BIOTECH | 270.18 | 51.49 | 13,911.3 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 34.54 | 420,483.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 85.21 | 249,248.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 82.48 | 177,822.0 |
| CIPLA LTD | 3,364.84 | 31.33 | 105,427.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 31.08 | 98,492.3 |
| MANKIND PHARMA LTD | 2,055.11 | 48.20 | 99,064.7 |
| LUPIN LTD | 5,551.01 | 16.00 | 88,805.7 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 24.76 | 111,242.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 25.45 | 94,477.0 |
| LAURUS LABS LTD | 1,090.76 | 99.07 | 108,062.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs CONCORD BIOTECH 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 16.00x |
| Max industry PE | 99.07x |
| Median industry PE | 34.54x |
| Average industry PE | 48.15x |
You may also like the below Video Courses